Patients with pulmonary arterial hypertension experienced a significant improvement in World Health Organization Functional Class when transitioned from a phosphodiesterase type 5 inhibitor to riociguat.
When used as needed, the combination of budesonide-formoterol was found to be superior to albuterol for the prevention of asthma exacerbations in patients with mild asthma.
Positive results with respect to the presence of latent tuberculosis infection in patients with renal failure were more consistent with the use of QuantiFERON-TB Gold Plus testing compared with the use of QuantiFERON-TB Gold In-Tube testing.
Umeclidinium improved all lung function measures compared with salmeterol in patients with COPD who were naive to maintenance therapy or who were treated with a single maintenance bronchodilator.
Use of the dry powder formulation of treprostinil, known as LIQ861, has demonstrated safety and tolerability in patients with pulmonary arterial hypertension beyond 2 weeks.
Combination treatment with ambrisentan and tadalafil is associated with a reduced mortality risk profile in patients with scleroderma-associated pulmonary arterial hypertension.
Patients with corticosteroid-dependent severe asthma who received dupilumab had better asthma control and health-related quality of life compared with those who received placebo.
Echocardiographic right atrial area improved the risk stratification of a simplified risk assessment tool designed to predict survival in patients with pulmonary arterial hypertension.
In patients with pulmonary arterial hypertension, factors that affect prognosis but not treatment response included age, gender, and connective tissue disease-PAH etiology.
Based on the 2016 International Working Group (IWG) diagnostic criteria for idiopathic pulmonary fibrosis (IPF), outcomes are relatively similar between patients with IPF with pneumonia and patients with an acute IPF exacerbation.
